Related Experiment Video
Updated: Sep 11, 2025

Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis
Published on: July 4, 2007
Self-reported cognitive dysfunction and memory impairment in Systemic Autoimmune Rheumatic Diseases (SARDs): a mixed
Avni Varshney1, Thomas A Pollak1, Arjoon Arunasalam1
1Institute of Psychiatry, Psychology and Neuroscience, King's College London, South London and Maudsley NHS Foundation Trust, London, UK.
Objectives:
To explore self-reported cognitive dysfunction, including memory impairment, across systemic autoimmune rheumatic diseases (SARDs) and examine its impact and associations with demographic, clinical and psychosocial factors.
Methods:
A mixed-methods approach was employed, surveying 1853 SARD patients and 463 controls using validated instruments including the Everyday Memory Questionnaire-Revised (EMQ-R). Kruskal-Wallis tests and Spearman's rank correlations were used to compare the groups. Additionally, 67 in-depth interviews were conducted for qualitative thematic analysis.
Results:
Systemic lupus erythematosus (SLE), undifferentiated connective tissue disease (UCTD) and Sjögren's patients reported significantly higher rates of memory impairments than other groups. There was no evidence of increased self-reported memory impairment with disease duration or age. Moderate positive associations were found between EMQ scores and the lifetime frequency of all other neuropsychiatric symptoms. EMQ-R was positively associated with self-assessment of overall disease activity (r = 0.291, P < 0.001) and negatively correlated with well-being (r = -0.397, R2 = 0.159). Expanding on the quantitative findings, qualitative analyses highlighted the adverse impact of cognitive dysfunction on daily participation in activities, social isolation, self-esteem and mental well-being, and the potential underreporting of these symptoms to clinicians.
Conclusion:
This study highlights a significant impairment of memory in SARDs, notably in SLE, UCTD and Sjögren's, and the impact of cognitive impairment on daily lives and well-being. The positive associations with disease activity and neuropsychiatric symptoms, and negative association with well-being emphasizes the need for targeted interventions. Future research should prioritize developing pharmacological and psychosocial interventions to address cognitive dysfunction in SARD patients. While reassuringly there was no evidence of worsening memory impairment over time, the underreporting of symptoms also suggests that cognitive issues may be more prevalent than clinical records indicate and thus emphasize the importance of thorough patient assessment.
Related Concept Videos
Autoimmune Disorders
Concept and Mechanism of Autoimmune Diseases
The immune...
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Rheumatic Heart Disease I: Introduction
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Psychoneuroimmunology: Cardiovascular Disease
A key area of focus in PNI is the relationship between stress and coronary...

